CLINICAL TRIALS PROFILE FOR SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
✉ Email this page to a colleague
All Clinical Trials for SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | US Department of Veterans Affairs | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
| NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | VA Office of Research and Development | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
| NCT00224549 ↗ | PHARES Study: Management of Resistant Hypertension | Completed | Assistance Publique - Hôpitaux de Paris | Phase 4 | 2005-04-01 | The purpose of this study is to assess the efficacy of two different treatment regimens for treating resistant hypertension previously uncontrolled with at least 3 antihypertensive treatments. The study hypothesis is that these two regimens (one based on increasing diuretics and the other based on increasing renin angiotensin system blockage) may not differ in terms of efficacy. |
| NCT00515021 ↗ | Diurnal Variation of Plasminogen Activator Inhibitor-1 | Completed | National Center for Research Resources (NCRR) | Phase 4 | 2007-04-01 | To determine if nighttime administration of an aldosterone antagonist would effectively lower peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning administration. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
Condition Name
Clinical Trial Locations for SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
Trials by Country
Clinical Trial Progress for SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
Clinical Trial Phase
Clinical Trial Sponsors for SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE
Sponsor Name
| Sponsor Name for SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE | |
| Sponsor | Trials |
| Vanderbilt University Medical Center | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| National Institutes of Health (NIH) | 1 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
